ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "interstitial lung disease"

  • Abstract Number: 824 • 2016 ACR/ARHP Annual Meeting

    Mycophenolate Versus Placebo for the Treatment of Systemic Sclerosis-Related Interstitial Lung Disease

    Elizabeth R. Volkmann1, Donald P. Tashkin2, Ning Li3, Michael Roth4, Dinesh Khanna5, Anna-Maria Hoffmann-Vold6, Philip J. Clements4, Daniel E. Furst1, Robert Elashoff7 and Scleroderma Lung Study II Group, 1University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 3UCLA, Los Angeles, CA, 4Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 5University of Michigan, Ann Arbor, MI, 6Oslo University Hospital, Oslo, Norway, 7Biomathematics, University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function and dyspnea in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).1 While treatment with…
  • Abstract Number: 2019 • 2016 ACR/ARHP Annual Meeting

    Faces in Motion: Clinical Subtyping in Scleroderma Using Changes in Forced Vital Capacity

    Colin Ligon1, Peter Schulam2, Suchi Saria3, Fredrick M. Wigley4, Robert Wise5 and Laura K. Hummers6, 1Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, PA, 2Johns Hopkins University, Baltimore, MD, 3Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 4Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, 5Department of Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, 6Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Prognostication in scleroderma has historically depended on using static measures such as antibody status and extent of skin involvement to stratify risk of mortality…
  • Abstract Number: 825 • 2016 ACR/ARHP Annual Meeting

    KL-6 and Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis Related Interstitial Lung Disease

    Gloria Salazar1, Masataka Kuwana2, Minghua Wu1, Jun Ying1, Julio Charles3, Maureen D Mayes1 and Shervin Assassi1, 1Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3Internal Medicine-Rheumatology, University of Texas-McGovern Medical School, Houston, TX

    Background/Purpose: Pneumoproteins are attractive biomarker candidates in systemic sclerosis (SSc) related interstitial lung disease (ILD) because they are easily obtainable and lung-specific.  KL-6 and CCL-18…
  • Abstract Number: 2310 • 2016 ACR/ARHP Annual Meeting

    The Predictive Risk Factors for Complication of Infection during the Treatment for Inflammatory Myopathies Complicated with Interstitial Lung Disease

    Yumiko SUGIYAMA1,2, Maasa Tamura1,2,3, Ryusuke Yoshimi1,2, Naoki Hamada1,2, Hideto Nagai1,2, Yuko Tatekabe1,2, Naomi Tsuchida2,4, Yutaro Soejima1,2, Yosuke Kunishita2,4, Daiga Kishimoto1,2, Hiroto Nakano1,2, Reikou Kamiyama1,2, Kaoru Minegishi2,5, Yukiko Asami1,2, Yohei Kirino2,4, Shigeru Ohno2,5 and Hideaki Nakajima1, 1Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Y-CURD Study Group, Yokohama, Japan, 3Nagaoka Red Cross Hospital, Nagaoka, Japan, 4Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan, 5Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan

    Background/Purpose:  Interstitial lung disease (ILD) is one of the predominant causes of death in polymyositis/dermatomyositis (PM/DM). We have already reported that low PaCO2 and interstitial…
  • Abstract Number: 830 • 2016 ACR/ARHP Annual Meeting

    Cardiopulmonary Disease Development in Anti-RNA Polymerase III Positive Systemic Sclerosis; Comparative Analyses from an Unselected, Prospective Patient Cohort

    Anna Hoffmann-Vold1, Anders Heiervang Tennøe2, Oyvind Midtvedt2, May Brit Lund3, Torhild Garen2, Fadi El-Hage4, Trond Mogens Aalokken5, Eli Taraldsrud4 and Øyvind Molberg2, 1Division of Rheumatology, Oslo University Hospital, Oslo, Norway, 2Rheumatology, Oslo University Hospital, Oslo, Norway, 3Respiratory Medicine, Oslo University Hospital, Oslo, Norway, 4Oslo University Hospital, Oslo, Norway, 5Radiology, Oslo University Hospital, Oslo, Norway

    Background/Purpose: Extensive skin disease and renal crisis are hallmarks of anti-RNA polymerase III (RNAP) positive systemic sclerosis (SSc), while data on lung and heart involvement…
  • Abstract Number: 2311 • 2016 ACR/ARHP Annual Meeting

    Initial Predictors of Short-Term Poor Survival Rates in Patients with Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease

    Shinji Sato1, Kenichi Masui2, Naoshi Nishina3, Yasushi Kawaguchi4, Atsushi Kawakami5, Maasa Tamura6, Kei Ikeda7, Takahiro Nunokawa8, Yoshinori Tanino9, Katsuaki Asakawa10, Yuko Kaneko11, Takahisa Gono12, Masataka Kuwana3 and JAMI investigators, 1Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, 2Department of Anesthesiology, National Defense Medical College School of Medicine, Tokorozawa, Japan, 3Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 4Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 5Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 6Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 7Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, 8Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, 9Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan, 10Division of Respiratory Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan, 11Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 12Department of Rheumatology, Jichi Medical University Saitama Medical Center, Saitama, Japan

    Background/Purpose: Polymyositis (PM)/dermatomyositis (DM) is a chronic inflammatory disorder that affects muscle, skin and lung in various degree, and interstitial lung disease (ILD) is a…
  • Abstract Number: 831 • 2016 ACR/ARHP Annual Meeting

    Immunosuppression May Prevent Interstitial Lung Disease in Systemic Sclerosis

    Sabrina Hoa1, Marie Hudson2, Mianbo Wang3, Russell Steele4, Murray Baron5 and Canadian Scleroderma Research Group, 1Division of Rheumatology, Jewish General Hospital, Lady Davis Institute, Montreal, QC, Canada, 2Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, 3Lady Davis Institute for Medical Research, Montreal, QC, Canada, 4Mathematics, McGill University, Montreal, QC, Canada, 5Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada

    Background/Purpose: Interstitial lung disease (ILD) is a leading cause of premature mortality in systemic sclerosis (SSc). Immunosuppression is used for treatment of established disease. However,…
  • Abstract Number: 2565 • 2016 ACR/ARHP Annual Meeting

    Common Biomarker Elevations in Idiopathic Pulmonary Fibrosis and Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Karen Fernandez1, Tracy Doyle2, Lisa Harlow3, Ivan O. Rosas4 and Dana P. Ascherman5, 1Rheumatology, University of Miami Miller School of Medicine, Miami, FL, 2Medicine/Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, 3Rheumatology and Clinical Immunology, University of Miami Miller School of Medicine, Miami, FL, 4BWH - Pulmonary, Brigham and Women's Hospital, Boston, MA, 5Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL

    Background/Purpose:  Interstitial lung disease (ILD) is an extra-articular manifestation of rheumatoid arthritis (RA) which contributes to increased morbidity and mortality. Clinico-epidemiological data indicate some overlap…
  • Abstract Number: 843 • 2016 ACR/ARHP Annual Meeting

    Forced Vital Capacity Predicts Outcome in Scleroderma Associated Interstitial Lung Disease with Concomitant Pulmonary Hypertension:  Data from the Pharos Registry

    Joyce Sujin Lee1, Jessica K. Gordon2, Jackie Szymonifka3, Virginia Steen4 and Aryeh Fischer5, 1SOM-MED, University of Colorado, Denver - Anschutz Medical Campus, Aurora, CO, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, 4Georgetown University School of Medicine, Washington, DC, 5Medicine / Center for Lungs and Breathing, University of Colorado School of Medicine, Aurora, CO

    Forced vital capacity predicts outcome in scleroderma associated interstitial lung disease with concomitant pulmonary hypertension:  Data from the PHAROS registry Background/Purpose:   Interstitial lung disease…
  • Abstract Number: 2891 • 2016 ACR/ARHP Annual Meeting

    Prognostic Significance of Autoantibody Positivity in Interstitial Lung Disease: A Retrospective Case-Control Study

    Christos F Kampolis1, Aliki I Venetsanopoulou1, Fotini Karakontaki2, Vlassis Polychronopoulos2, Panayiotis G Vlachoyiannopoulos1 and Athanasios G. Tzioufas3, 1Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 2Respiratory Medicine, “Hygeia” Hospital, Athens, Greece, 3School of Medicine, Pathophysiology Department, National and Kapodistrian University of Athens, Athens, Greece

    Background/Purpose:  Routine screening for circulating autoantibodies (AAbs) on the initial evaluation of interstitial lung disease (ILD) contributes to the diagnosis of underlying autoimmune disease. However,…
  • Abstract Number: 845 • 2016 ACR/ARHP Annual Meeting

    Current Use of Off-Label Therapies in Systemic Sclerosis-Associated Interstitial Lung Disease

    Elise Siegert1, Dörte Huscher2, Ulf Müller-Ladner3, Veronika K. Jaeger4, Ulrich A. Walker4, Marc Frerix5, László Czirják6, Francesco Del Galdo7, Gabriele Valentini8, Marco Matucci-Cerinic9, Yannick Allanore10, Oliver Distler11, Christopher Denton12, Gabriela Riemekasten13 and EUSTAR co-authors, 1Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, 2Epidemiology, German Rheumatism Research Centre, Berlin, Germany, 3Department of Internal Medicine and Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, 4Department of Rheumatology, University Hospital Basel, Basel, Switzerland, 5Department of Rheumatology and Clinical Immunology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, 6Department of Rheumatology and Immunology, University of Pécs, Faculty of Medicine, Pécs, Hungary, 7Musculoskeletal Diseases, Scleroderma Research Program, Leeds Institute of Molecular Medicine, Division of Musculoskeletal Diseases, University of Leeds, Leeds, United Kingdom, 8Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, 9Department of Medicine, Division of Rheumatology, University of Florence, Florence, Italy, 10Rheumatology, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 11Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 12Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, 13Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany

    Background/Purpose: Systemic Sclerosis (SSc) is a connective tissue disease that is often complicated by secondary interstitial lung disease (SSc-ILD). Due to its high morbidity and…
  • Abstract Number: 2892 • 2016 ACR/ARHP Annual Meeting

    Serum Level of KL-6, a Biomarker of Interstitial Lung Disease (ILD), Is Higher in Diffuse SSc Than in Limited SSc and RA Even When the Activity of ILD Is Low

    Tamao Nakashita1, Shinji Motojima2, Akira Jibatake2, Akira Yoshida2 and Yoshiki Yamamoto2, 1Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan, 2Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan

    Background/Purpose:  KL-6 is a glycoprotein expressed on and released from type 2 alveolar cells and the measurement of KL-6 in serum was developed by Kohno…
  • Abstract Number: 847 • 2016 ACR/ARHP Annual Meeting

    Forced Vital Capacity Predicts Lung Fibrosis Progression and Mortality in Systemic Sclerosis

    Anna Hoffmann-Vold1, Elizabeth R. Volkmann2, Oyvind Midtvedt3, Torhild Garen3, Anders Heiervang Tennøe3, Trond Mogens Aalokken4, May Brit Lund5 and Øyvind Molberg3, 1Division of Rheumatology, Oslo University Hospital, Oslo, Norway, 2University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 3Rheumatology, Oslo University Hospital, Oslo, Norway, 4Radiology, Oslo University Hospital, Oslo, Norway, 5Respiratory Medicine, Oslo University Hospital, Oslo, Norway

    Background/Purpose:  Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD), but there are no valid methods for early detection of SSc-ILD or…
  • Abstract Number: 2904 • 2016 ACR/ARHP Annual Meeting

    Rituximab in Systemic Sclerosis-Interstitial Lung Disease, a Case Series of 18 Patients

    Gul Guzelant1, Melike Melikoglu1, Benan Musellim2, Deniz Demir Yilmaz2, Izzet Fresko1, Emire Seyahi1, Gulen Hatemi1, Serdal Ugurlu1 and Vedat Hamuryudan1, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Pulmonary Medicine, Istanbul, Turkey

    Background/Purpose: Interstitial lung disease (ILD) is a severe complication of systemic sclerosis (SSc). Immunosuppressives such as cyclophosphamide (CYC) and mycophenolate mophetil (MMF) are used in…
  • Abstract Number: 852 • 2016 ACR/ARHP Annual Meeting

    Targeting Fibroblastoid-like Cells By Drug Loaded Engineered Gold Nanoparticles As a Novel Approach for ILD-SSc Treatment

    Veronica Codullo1, Emanuela Cova2, Simona Inghilleri2, Miriam Colombo3, Davide Prosperi3, Federica Meloni4 and Carlomaurizio Montecucco5, 1Division of Rheumatology, University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, 2Clinica di Malattie dell’Apparato Respiratorio, IRCCS Fondazione Policlinico S Matteo, Pavia, Italy, Pavia, Italy, 3Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Milan, Italy, 4Dipartimento di Medicina Interna, Unità di Pneumologia e UOC di Reumatologia, Università di Pavia, Pavia, Italy, 5Rheumatology Unit of the University Hospital of Pavia, Pavia, Italy

    Background/Purpose:  Systemic Sclerosis (SSc) is an autoimmune fibrotic disorder characterised by collagen and extracellular matrix deposition in the skin and internal organs, such as the…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies